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Abstract
The studies presented in this short communication demonstrate that an aqueous extract of rosehip from Rosa canina L. inhibited the 
chemotaxis as well as chemiluminescence of human peripheral blood leukocytes in vitro. Using a bioassay-guided fraction of the extract, 
the active principle was shown to be a galactolipid named GOPO®. These in vitro studies demonstrate that rosehip powder exhibits anti-
inﬂ ammatory as well as anti-oxidant activities. 
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Introduction
Rosehip or fruits of dog rose (Rosa canina L.) has been 
used as a source of vitamin C in tea and other products 
for many years. The British Herbal Pharmacopoeia (1983) 
notes that rosehip has properties, which can be used for 
gastritis, diarrhea, polydipsia and vitamin C deﬁ ciency. Some 
undocumented claims have also been made that rosehip 
may reduce the pain in patients suffering from inﬂ ammatory 
diseases such as osteoarthritis. The present drugs such 
as acetylsalicylic acid, non-steroid anti-inﬂ ammatory drugs 
and glucocorticoids used for the alleviation of the symptoms 
associated with this disease are claimed to exhibit a variety 
of side effects such as gastric erosion and adverse effects 
on the kidneys and liver. Therefore, it is necessary to ﬁ nd 
drugs or remedies, which are free from side effects and 
help to provide these patients with relief from pain and other 
symptoms. 
Methods
Rosehip powder. A standardized rosehip powder from 
Rosa canina L. prepared by a special drying process 
provided by Hyben Vital, Langeland, Denmark was used 
throughout these studies.
Cells. Polymorphonuclear leukocytes (PMNs) were 
isolated from the peripheral blood of either healthy subjects 
or osteoarthritis patients, suspended in appropriate culture 
medium and used for biological activity assays.  
Chemotaxis. A chemotaxis assay was performed using 
a modiﬁ ed Boyden chamber technique. The puriﬁ ed PMNs 
were pre-incubated with different dilutions of rosehip 
powder, various concentrations of the active compound
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GOPO® or control medium for 30 min at 37°C. Following 
pre-incubation, the chemotaxis of the cells towards the 
chemotactic factor zymosan activated serum (ZAS), 
which contains the biologically active chemo-attractant 
C5a, were tested. The migrated cells were counted by a 
computer-assisted image analysis system. The inhibition of 
chemotaxis was determined as the percentage of the cell 
response in the control culture medium.1
Chemiluminescence. A chemiluminescence assay was 
used as a measure of oxygen radical generation by activated 
PMNs. The cells were pre-incubated with different dilutions 
of rosehip powder, various concentrations of GOPO® or 
control medium for 30 min at 37°C and then stimulated with 
opsonized zymosan. The oxidative burst response of the 
activated cells was then measured by a luminometer. The 
inhibition of chemiluminescence was determined as the 
percentage of response in the control culture medium.2
Cell viability. Cell viability was determined by a trypan 
blue dye exclusion method. The dead cells take up the dye 
and appear blue under the microscope.
Isolation of GOPO®. GOPO® was isolated from the dried 
and milled fruits of dog rose by sequential extraction with 
n-hexane, dichloromethane, methanol and water, and the 
extracts evaporated in vacuo to dryness. Following testing 
of the resulting residues in the bioassay it was found that 
the activity was conﬁ ned to the dichloromethane extract. 
The active ingredient was isolated using bioassay-guided 
fractionation by open column chromatography on silica 
gel followed by preparative HPLC. The structure of the 
active compound was elucidated from 1D and 2D NMR 
data.3
Results and Discussion
Our group has been involved in research on rosehip 
powder for the past 10 years. We have shown that a powder 
prepared from rosehip, Rosa canina L., developed in 
Denmark, inhibited the chemotaxis and chemiluminescence 
of human PMNs in vitro as shown in Figs 1 and 2.4,5  Daily 
intake of the powder for four weeks by healthy volunteers 
and patients suffering from osteoarthritis resulted in 
decreased chemotaxis of PMNs and a reduced level of the 
inﬂ ammatory marker acute phase C-reactive protein (CRP) 
in these subjects.4,5
Several double-blind, placebo-controlled clinical studies 
(presented in the following article) showed that rosehip 
powder exhibited several beneﬁ cial effects such alleviating 
pain and improving general wellbeing, sleep quality and 
mood in these patients.6–8
Studies from other groups have also shown that the 
extract of Rosa canina L. inhibited the respiratory burst 
of human PMNs9 and exhibited an inhibitory effect on 
inﬂ ammatory cytokines such as interleukin-1 and tumor 
necrosis alpha.10
Using a bioassay-guided fraction we have identiﬁ ed the 
active anti-inﬂ ammatory and anti-oxidant principle in the 
rosehip. Using NMR this compound was identiﬁ ed as a 
galactolipid (2S)-1,2-di-O-[(9Z,12Z,15Z)-octadeca-9,12,15-
trienoyl]-3-O−B-D-galactopyranosy glycerol, which was 
named GOPO®. The molecular weight of the compound 
is 775 g/mol.3 The structure of the compound is shown in 
Fig. 3.
The content of GOPO® varies considerably in different sub-
types of rosehip. The content of GOPO® in the standardized 
Hyben Vital rosehip used in our studies is quite high. This 
is due to a patent-protected drying process, which has 
been used to prepare the Hyben Vital rosehip in order to 
ensure that the active component GOPO® is preserved 
and is available in the ﬁ nished product.  Other methods for 
processing the rosehip powder might destroy this essential 
compound, which means that commonly available rosehip 
products might not produce the same effects as have been 
illustrated in the studies using a specially processed and 
standardized rosehip powder from Rosa canina L.
As shown in Table I GOPO® inhibited the chemotaxis 
and oxidative burst response of PMNs at microgram 
concentrations, demonstrating the anti-inﬂ ammatory and 
anti-oxidant properties of the compound. Cell viability tests 
showed that the PMNs were viable even at the highest 
concentration used in these studies indicating that the 
inhibition of cell migration and the oxidative burst response 
was not related to toxicity. 
These data indicate that GOPO® has the potential to 
be developed into a new anti-inﬂ ammatory drug for the 
treatment of inﬂ ammatory diseases, such as rheumatoid 
arthritis and osteoarthritis.  Studies are in progress to 
develop GOPO®-enriched new products.
Fig. 1. The effect of rosehip powder on chemotaxis response of 
PMNs.
Fig. 2. The effect of rosehip powder on chemiluminescence 
response of PMNs.
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Fig. 3. The structure of GOPO®.
Table I
The effect of GOPO® on chemotaxis and chemiluminescence response of PMNs
GOPO® concentrations
(µg/ml)
Chemotaxis
(% Inhibition)
Chemiluminescence
(% Inhibition)
Cell viability
(% Viable cells)
50 99 37   99
25 52 19 100
10 62 13   99
  1 64 NC  NC
 0.1   7 NC  NC
 0   0   0 100
NC: not completed.
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The recent withdrawal of Vioxx, one of the major drugs 
for osteoarthritis, by Merck, Sharpe and Dohme due to 
serious side effects, raised concerns about the whole 
group of synthetic Cox-2 inhibitors, which rofecoxib 
belongs to. It is therefore important that in contrast to 
NSAIDs and acetylsalicylic acid, rosehip powder does not 
inhibit platelets and does not inﬂ uence ﬁ brinolysis or the 
coagulation cascade. This is a signiﬁ cant beneﬁ t for patients 
with cardiovascular conditions who are often limited in the 
availability of safe and effective pain medications due to the 
increased cardiovascular disease risk of long-term rofecoxib 
usage.
In conclusion, the specially processed and standardized 
rosehip powder from Rosa canina L. might provide a safer 
alternative for millions of patients suffering from osteoarthritis 
and other inﬂ ammatory diseases.
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